Transcode Therapeutics Submits IND Amendment for Phase 2a Clinical Trial of Lead Candidate TTX-MC138
Summary
Transcode Therapeutics announced the submission of an IND amendment for a planned Phase 2a clinical trial of its lead candidate, TTX-MC138, in collaboration with Quantum Leap Healthcare Collaborative.
Key Events
-
IND Amendment Submitted for Phase 2a Trial
Transcode Therapeutics, in collaboration with Quantum Leap Healthcare Collaborative, submitted an Investigational New Drug (IND) application amendment to the FDA for a planned Phase 2a clinical trial of its lead therapeutic candidate, TTX-MC138.
-
Trial Targets Colorectal Cancer with MRD
The Phase 2a trial will enroll up to 45 patients with colorectal cancer who have completed standard curative-intent therapy and have positive markers for circulating tumor DNA (ctDNA), indicating minimal residual disease (MRD).
-
Collaboration with Quantum Leap Healthcare Collaborative
The study will be conducted within Quantum Leap's PRE-I-SPY program, marking its first expansion into colorectal cancer and providing a robust platform for innovative oncology clinical trials.
-
Trial Expected to Begin in First Half of 2026
The Phase 2a clinical trial is planned to commence in the first half of 2026, led by Principal Investigator Dr. Paula Pohlmann of MD Anderson Cancer Center.
Analysis
This filing marks a significant advancement for Transcode Therapeutics as it progresses its lead therapeutic candidate, TTX-MC138, into a planned Phase 2a clinical trial. The submission of an IND amendment to the FDA, following preclinical research announced on January 6, 2026, is a critical step in the drug development process for a clinical-stage biotech company. The collaboration with Quantum Leap Healthcare Collaborative and their PRE-I-SPY program adds credibility and resources to the trial, which will focus on colorectal cancer patients with circulating tumor DNA (ctDNA), a key prognostic marker for recurrence. This move into a more advanced clinical stage for a lead candidate is a positive signal for the company's pipeline and future prospects.
At the time of this filing, RNAZ was trading at $9.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.9M. The 52-week trading range was $6.08 to $399.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.